EANS-News: Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products

Vienna, Austria, October 30, 2009 (euro adhoc) - Intercell AG (VSE:
ICLL) today announced that the Health Canada granted product approval
for IXIARO®, the company's vaccine to prevent Japanese Encephalitis
(JE).

This decision of the Canadian authorities represents another
important milestone for the product's global reach. Intercell's
vaccine to prevent Japanese Encephalitis has already been
successfully approved and launched in the USA, Europe and Australia.

"We are very pleased that IXIARO is now also approved by the Canadian
authorities. This reflects another step in growing our IXIARO
business by supplying this important product to travelers", states
Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Intercell's Japanese Encephalitis vaccine will be available for the
Canadian market by the end of the year and will be distributed and
marketed to travel clinics by Novartis Pharmaceuticals Canada Inc.
and to the military personnel by Intercell.

IXIARO is a purified, inactivated product for active immunization
against infection by the Japanese Encephalitis Virus. IXIARO is
manufactured at Intercell's proprietary manufacturing facility in
Scotland and is prepared using tissue culture rather than live
organisms.

About Japanese Encephalitis

Japanese Encephalitis (JE) is a deadly infectious disease found
mainly in Asia. Approximately 30,000 to 50,000 cases of JE are
reported in Asia each year, and the actual number of cases are likely
much higher due to underreporting in rural areas. JE is fatal in
approximately 30 percent of those who show symptoms and leaves half
of survivors with permanent brain damage. As there is no specific
treatment for JE, vaccination is the only effective protection for
the millions of travelers and military personnel who live in or
travel to areas where the virus circulates.

About IXIARO

Intercell's novel Japanese Encephalitis vaccine is a purified,
inactivated vaccine for active immunization of adults against the
Japanese Encephalitis virus. The vaccine was developed under a
Collaborative Research and Development Agreement with the Walter Reed
Army Institute of Research, a biomedical research laboratory for the
U.S. Department of Defense.

Intercell's Phase III trials for IXIARO found that the vaccine
demonstrated immunogenicity against Japanese Encephalitis and an
overall clinical safety profile similar to the control arm, combined
with an excellent local tolerability profile. These data were
published in The Lancet in December 2007:

» The immunogenicity was comparable to that of the U.S. licensed
product, JE-VAX®. » Intercell's vaccine demonstrated an overall
clinical safety profile similar to the control arm. » Further,
Intercell's Japanese Encephalitis vaccine had a more favorable
local tolerability profile in the head-to-head study with JE-VAX®.

Please refer to the Product / Prescribing information (PI) /
Medication Guide approved in your respective countries for complete
information including safety about this vaccine.

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market